Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:PGNY

Progyny (PGNY) Stock Price, News & Analysis

Progyny logo
$28.97 -0.15 (-0.52%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$28.97 +0.00 (+0.01%)
As of 10/23/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Progyny Stock (NASDAQ:PGNY)

Advanced

Key Stats

Today's Range
$28.80
▼
$29.11
50-Day Range
$24.79
▼
$29.12
52-Week Range
$16.10
▼
$33.06
Volume
565,756 shs
Average Volume
1.10 million shs
Market Capitalization
$2.22 billion
P/E Ratio
31.49
Dividend Yield
N/A
Price Target
$34.36
Consensus Rating
Moderate Buy

Company Overview

Progyny, Inc. is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States. The company was founded in 2015 and became a publicly traded company on the Nasdaq in 2019. Peter Anevski serves as chief executive officer, having previously held senior financial and operational roles at the company.

AI Generated. May Contain Errors.

Progyny Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

PGNY MarketRank™: 
3.51307847082 of 5 stars

Progyny scored higher than 70% of companies evaluated by MarketBeat, and ranked 208th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Progyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 9 buy ratings, 4 hold ratings, and no sell ratings.

  • Upside Potential

    Progyny has a consensus price target of $34.36, representing about 18.6% upside from its current price of $28.97.

  • Amount of Analyst Coverage

    Progyny has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Progyny's stock forecast and price target.
  • Earnings Growth

    Earnings for Progyny are expected to grow by 13.60% in the coming year, from $1.25 to $1.42 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Progyny is 31.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.38.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Progyny is 31.49, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.33.

  • Price to Earnings Growth Ratio

    Progyny has a PEG Ratio of 2.00. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Progyny has a P/B Ratio of 4.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Progyny's valuation and earnings.
  • Percentage of Shares Shorted

    7.36% of the float of Progyny has been sold short.
  • Short Interest Ratio / Days to Cover

    Progyny has a short interest ratio ("days to cover") of 4.09.
  • Change versus previous month

    Short interest in Progyny has recently increased by 8.14%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Progyny does not currently pay a dividend.

  • Dividend Growth

    Progyny does not have a long track record of dividend growth.

  • News Sentiment

    Progyny has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Progyny this week, compared to 4 articles on an average week.
  • Search Interest

    5 people have searched for PGNY on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 2 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $475,790.00 in company stock.

  • Percentage Held by Insiders

    9.90% of the stock of Progyny is held by insiders.

  • Percentage Held by Institutions

    94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Progyny's insider trading history.
Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PGNY Stock News Headlines

Progyny (PGNY) Gets a Buy from Wells Fargo
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
Leerink Partners Sticks to Its Buy Rating for Progyny (PGNY)
Progyny (NASDAQ:PGNY) EVP Sells 3,903 Shares of Stock
See More Headlines

PGNY Stock Analysis - Frequently Asked Questions

Progyny's stock was trading at $25.68 at the start of the year. Since then, PGNY stock has increased by 12.8% and is now trading at $28.97.

Progyny, Inc. (NASDAQ:PGNY) issued its earnings results on Thursday, August, 6th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.33 by $0.22. The company's quarterly revenue was up 5.3% compared to the same quarter last year.
Read the conference call transcript
.

Progyny's board approved a stock buyback program on Tuesday, May 26th 2026, which allows the company to buy back $200,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 10.3% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's management believes its stock is undervalued.

Progyny (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Progyny's top institutional investors include Fort Washington Investment Advisors Inc. OH (2.13%), Pinnacle Associates Ltd. (0.05%), Prime Capital Investment Advisors LLC (0.03%) and State of Alaska Department of Revenue (0.02%). Insiders that own company stock include Peter Anevski, Michael E Sturmer, David J Schlanger, Allison Swartz, Mark S Livingston, Melissa B Cummings, Geoffrey Clapp, Cheryl Scott and Kevin K Gordon.
View institutional ownership trends
.

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Fortinet (FTNT), Tradeweb Markets (TW), Tesla (TSLA), NVIDIA (NVDA), Palantir Technologies (PLTR), Roku (ROKU) and Salesforce (CRM).

Company Calendar

Last Earnings
8/06/2026
Today
10/25/2026
Next Earnings (Estimated)
11/04/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:PGNY
CIK
1551306
Fax
N/A
Employees
856
Year Founded
2008

Price Target and Rating

High Price Target
$40.00
Low Price Target
$30.00
Potential Upside/Downside
+18.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.92
Trailing P/E Ratio
31.49
Forward P/E Ratio
23.18
P/E Growth
2
Net Income
$58.52 million
Net Margins
6.00%
Pretax Margin
9.14%
Return on Equity
15.98%
Return on Assets
10.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.14
Quick Ratio
2.14

Sales & Book Value

Annual Sales
$1.29 billion
Price / Sales
1.72
Cash Flow
$0.74 per share
Price / Cash Flow
39.35
Book Value
$5.99 per share
Price / Book
4.84

Miscellaneous

Outstanding Shares
76,730,000
Free Float
69,131,000
Market Cap
$2.22 billion
Optionable
Optionable
Beta
1.02

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:PGNY) was last updated on 10/23/2026 by MarketBeat.com Staff.
From Our Partners